Advanced Medicine

The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR T picture… We examine what’s going on in advanced medicine.

Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.

Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.

Sitting Down With... Miguel Forte, Chief Executive Officer at Bone Therapeutics, Belgium, to discuss advanced medicine.

Aseptic filling is the final manufacturing step but it shouldn’t be an afterthought.

UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.